Ondansetron Hydrochloride Dihydrate, CAS 103639-04-9, empirical formula C₁₈H₁₉N₃O·HCl·2H₂O, molecular weight 365.85 g/mol, is the compendial salt form of the selective 5-HT₃ receptor antagonist ondansetron base, CAS 99614-02-5. The substance is supplied as a white to almost white crystalline powder and is the active pharmaceutical ingredient for tablet, capsule, granule, oral liquid, and injectable dosage forms. Compendial identity is established by the USP Ondansetron Hydrochloride monograph and the Ph. Eur. monograph for Ondansetron hydrochloride dihydrate. The theoretical water content from the dihydrate stoichiometry is 9.85% w/w, and the free base content of the salt is approximately 80.2% w/w; strength calculations for formulated batches must therefore be converted to ondansetron free base equivalents. Ondansetron Hydrochloride Dihydrate differs from ondansetron free base in that the salt provides reproducible aqueous solubility, defined hydrate water content, and a compendial reference for assay, related substances, residual solvents, and water determination. The API is used in dosage strengths including 4 mg, 8 mg, and 24 mg oral solid units and 2 mg/mL injection, with strength expressed as ondansetron base.

Monograph compliance alone does not define processability for solid oral dosage forms. The USP and Ph. Eur. monographs do not establish a particle-size specification; D10, D50, and D90 values are therefore agreed as buyer-seller specifications based on the intended manufacturing route. For direct compression of low-dose tablets, segregation risk is controlled by matching API particle size to excipient carrier size and by the use of forced feeder and high-speed rotary press conditions. Powder flow is evaluated using USP <1174> powder flow methods, with compressibility index and Hausner ratio as decision variables. Adequate flow is supported when compressibility index remains at or below 25% and Hausner ratio remains at or below 1.35; values above these thresholds indicate that a granulation step, roller compaction, or addition of glidant such as colloidal silicon dioxide should be introduced. Published data for this specific API configuration is limited because particle-size targets are product-specific rather than pharmacopoeial.

Wet granulation is frequently selected for ondansetron hydrochloride dihydrate because the API can exhibit acicular or needle-like crystal habit depending on crystallisation solvent and cooling rate. That morphology can reduce bulk density and increase interparticle friction during low-shear blending. High-shear granulation with lactose monohydrate and microcrystalline cellulose produces densified granules with improved content uniformity. The aqueous solubility of the hydrochloride dihydrate allows the API to be dissolved in the granulating fluid or dispersed as a micronized suspension; the choice affects drug distribution in the granule. If the API is dissolved in purified water for granulation, the binder solution should be used immediately to avoid pH-dependent precipitation of ondansetron free base. Strongly alkaline granulating fluids are incompatible because they can reduce hydrochloride salt solubility and precipitate the free base.

Water content is a critical release and in-process parameter. The dihydrate form contains 9.85% w/w theoretical water; routine release specification is commonly set at 9.0% w/w to 10.5% w/w by Karl Fischer titration according to USP <921> or Ph. Eur. 2.5.12. Drying of finished granules is controlled separately from the API water content. Final granulate loss on drying is typically specified at or below 2.0% w/w to prevent sticking during tablet compression and to preserve capsule shell integrity. Drying temperatures above 60 °C can accelerate reduction of water content and may contribute to hydrate loss if the process is not terminated when the granulate reaches target residual moisture. Loss of dihydrate water alters assay calculation on the dried basis and can change crystal lattice dimensions, affecting stability and dissolution.

Analytical control for solid oral use includes assay by high-performance liquid chromatography using USP <621> or Ph. Eur. 2.2.29, with acceptance limits of 98.0% to 102.0% on the dried basis. Related substances are controlled by the same HPLC methods against monograph limits. Residual solvents are controlled according to USP <467> or Ph. Eur. 2.4.24; Class 3 solvents are typically limited to not more than 0.5% w/w per solvent. Tablet content uniformity and dissolution are finished-product tests performed according to USP <905> and USP <711>, respectively. Ondansetron Hydrochloride Dihydrate is compatible with common tablet and capsule excipients including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, and magnesium stearate. The substance is not intrinsically sterile; for solid oral products, microbial enumeration testing by USP <61> and <62> or Ph. Eur. 2.6.12 and 2.6.13 is applied, with total aerobic microbial count not exceeding 100 CFU/g and total yeast and mold count not exceeding 20 CFU/g.

In fluid-bed granulation of oral granules, ondansetron hydrochloride dihydrate is frequently dissolved in the binder solution or sprayed as a finely dispersed slurry onto mannitol, sucrose spheres, or microcrystalline cellulose cores using top-spray or tangential-spray equipment. The API has a bitter taste; granules intended for oral suspension or dispersible use therefore require a taste-masking barrier. pH-dependent polymers such as Eudragit E PO are applied at thicknesses sufficient to limit release in saliva at oral pH 6.8 to 7.4 while permitting dissolution in gastric fluid below pH 5.0. Fluid-bed inlet air temperature is typically maintained at 50 °C to 70 °C, with product temperature held below 45 °C to reduce amorphous generation and hydrate stress; these limits must be confirmed against batch-specific stability data rather than transferred from other APIs. Granule size distribution for oral suspension is controlled by sieve analysis, with target retain fractions established by dissolution and suspension uniformity studies. Granules are filled into sachets or unit-dose containers under low-humidity conditions because the finished granulate, unlike the API itself, is moisture-sensitive with respect to color and flow. In oral liquid manufacturing, the hydrochloride dihydrate is dissolved in purified water and buffered to an acidic pH to suppress free base precipitation. Clarified solution is passed through a 0.45 µm or tighter filter before filling. Light protection and tight container closure are required based on compendial storage statements for ondansetron drug products.

Parenteral manufacture begins with a nonsterile API that must support terminal sterilization or aseptic filtration of the finished injection. Injectable-grade Ondansetron Hydrochloride Dihydrate adds several controls not applied to all oral grades. Bacterial endotoxin testing is performed according to USP <85> or Ph. Eur. 2.6.14. The acceptance limit is derived from the maximum administered dose and the threshold of 5 EU/kg body weight for intravenous administration. For an ondansetron injection containing 2 mg/mL, a 16 mg maximum single dose in a 70 kg patient yields a calculated product endotoxin limit of approximately 21.9 EU/mg; an API limit of ≤ 0.5 EU/mg or tighter is commonly applied to provide margin for excipient contributions and manufacturing equipment hold time. Endotoxin limits are product-specific and must be justified through the finished-product risk assessment under ICH Q9, not copied from unrelated APIs.

Particulate matter in the finished injection is controlled by USP <788> or Ph. Eur. 2.9.19. The API supplier reduces particulate burden by controlling insoluble matter in the crystallized powder and by providing solution clarity after dissolution in water for injection. In compounding, Ondansetron Hydrochloride Dihydrate is dissolved at the required concentration, adjusted to pH within the finished injection range, and passed through a 0.22 µm sterilizing-grade filter before aseptic filling. The salt’s aqueous solubility permits manufacturing without organic cosolvents; solutions are compatible with 0.9% w/v sodium chloride injection and 5% w/v dextrose injection as vehicle components. Terminal sterilization by autoclaving is feasible for appropriately formulated ondansetron injection solutions, but exposure time and temperature should be confirmed against degradation kinetics. Published data for specific degradation rate constants is limited; batch-specific terminal sterilization hold-time studies are required.

Injectable-grade release also includes particulate, bioburden, and elemental impurity controls. Microbial enumeration of nonsterile API is performed by USP <61> and <62> or Ph. Eur. 2.6.12 and 2.6.13, with limits appropriate to a nonsterile starting material. If the finished injection is aseptically filtered, the API bioburden contributes to filter validation and should be controlled below the filter challenge load used in bacterial retention studies. Elemental impurities are managed according to USP <232> and <233> or ICH Q3D; limits for Class 1, Class 2A, Class 2B, and Class 3 elemental impurities are set on the basis of the permitted daily exposure and the maximum daily dose of ondansetron. The parenteral API is not required to be sterile, but uncontrolled bioburden above the validated prefilter load can compromise the sterility assurance level of the filled product.

The compendial dihydrate differs from ondansetron free base in several operational properties. Free base ondansetron has low aqueous solubility that limits dissolution and is not used directly in parenteral or aqueous granulation processes without salt formation. The hydrochloride dihydrate contains approximately 80.2% w/w ondansetron free base, and its water content is a defined hydrate component rather than surface moisture. The anhydrous hydrochloride salt, CAS 99614-01-4, is not a direct substitute for the dihydrate because water content calculations and assay on the dried basis differ; if the anhydrous form is used, the stoichiometric water correction must be removed and the analytical specification must be reassessed. Different suppliers of Ondansetron Hydrochloride Dihydrate may also differ in crystal habit, residual ethanol, particle-size distribution, and elemental impurity profile, even when all meet the same pharmacopoeial monograph. Supplier qualification under ICH Q7 and Q11 should therefore include X-ray powder diffraction, infrared identification, particle-size distribution, and full compendial release testing before process validation.

Compared with other 5-HT₃ antagonist APIs, ondansetron hydrochloride dihydrate is not mass-for-mass interchangeable. Granisetron hydrochloride, CAS 107007-99-8, has different molecular weight, salt content, and dose strength; palonosetron hydrochloride is a longer-acting 5-HT₃ antagonist with distinct receptor-binding kinetics and molecular structure. Direct formulation substitution among these APIs is not permitted without full pharmaceutical development, toxicological assessment, and regulatory variation. In a manufacturing context, the relevant difference is not clinical potency alone but the complete technical profile: solubility, crystallinity, water content, particle size, excipient compatibility, residual solvent class, and microbial control. Ondansetron Hydrochloride Dihydrate is selected when the target dosage form requires a highly water-soluble salt with defined hydrate water, compendial recognition across USP and Ph. Eur., and established analytical methods for HPLC assay and related substances. The API is suited to aqueous granulation, granule layering, oral solution compounding, and injectable solution preparation when route-specific endotoxin and bioburden specifications are applied.